733
edits
Heart Failure: Difference between revisions
→Pharmacological treatment
| Line 406: | Line 406: | ||
|bgcolor="99FFCC" align="center"|'''Aldosteron antagonist''' | |bgcolor="99FFCC" align="center"|'''Aldosteron antagonist''' | ||
|bgcolor="99FFCC"| | |bgcolor="99FFCC"| | ||
|bgcolor="9ACD32" align="center"|'''EF | |bgcolor="9ACD32" align="center"|'''EF ≤ 35%''' | ||
|bgcolor="9ACD32" align="center"|'''EF | |bgcolor="9ACD32" align="center"|'''EF ≤ 35%''' | ||
|bgcolor="9ACD32" align="center"|'''EF | |bgcolor="9ACD32" align="center"|'''EF ≤ 35%''' | ||
|- | |- | ||
|bgcolor="99FFCC" align="center"|'''Nitrate / Hydralazine''' | |bgcolor="99FFCC" align="center"|'''Nitrate / Hydralazine''' | ||
| Line 415: | Line 415: | ||
|bgcolor="9ACD32" align="center"|'''Afro-American''' | |bgcolor="9ACD32" align="center"|'''Afro-American''' | ||
|bgcolor="9ACD32" align="center"|'''Afro-American''' | |bgcolor="9ACD32" align="center"|'''Afro-American''' | ||
|- | |||
|bgcolor="99FFCC" align="center"|'''Ivabradine''' | |||
|bgcolor="99FFCC"| | |||
|bgcolor="9ACD32" align="center"|'''SR>75/min & EF<35%''' | |||
|bgcolor="9ACD32" align="center"|'''SR>75/min & EF<35%''' | |||
|bgcolor="9ACD32" align="center"|'''SR>75/min & EF<35%''' | |||
|- | |- | ||
|bgcolor="99FFCC" align="center"|'''Digoxin''' | |bgcolor="99FFCC" align="center"|'''Digoxin''' | ||